Emerging genetic factors and biomarkers associated with invisible illness susceptibility
HLA-DR4 and DR2 alleles are associated with treatment-resistant Lyme disease (post-treatment Lyme disease syndrome). Molecular mimicry between Borrelia outer surface protein A (OspA) and human LFA-1 may drive persistent autoimmune arthritis in DR4+ patients.
HLA-DRB1*15:01 is overrepresented in ME/CFS cohorts. Genome-wide association studies identify SNPs in TNF-alpha, IL-6, and interferon regulatory factor genes. Mitochondrial DNA haplogroups may influence disease susceptibility and severity.
The COMT Val158Met polymorphism (rs4680) affects catecholamine metabolism and pain sensitivity. The low-activity Met/Met genotype is associated with enhanced pain processing. 5-HTTLPR short allele in the serotonin transporter gene (SLC6A4) is linked to higher fibromyalgia prevalence and severity.
Strong familial clustering suggests polygenic inheritance. Up to 50% of POTS patients meet criteria for hypermobile Ehlers-Danlos syndrome (hEDS), implicating connective tissue genes (COL3A1, COL5A1, TNXB). Autoantibodies against adrenergic and muscarinic receptors found in familial cases.
ACE2 receptor polymorphisms (rs2285666, rs2106809) affect viral entry efficiency and post-infection immune dysregulation. HLA-DQB1*06:02 is associated with prolonged symptom duration. FOXP3 variants affecting T-regulatory cell function may predispose to persistent inflammation.
Genetic variation in IL-4, IL-13, and STAT6 signaling pathways influences IgE class-switching to alpha-gal epitopes. Prior lone star tick bites create cumulative sensitization through salivary galactose-alpha-1,3-galactose injection. Atopic individuals with high baseline IgE are at greatest risk.
| Biomarker | Condition | Discovery Stage | Sensitivity | Specificity |
|---|---|---|---|---|
| C6 Peptide ELISA | Lyme Disease | Validated | 93% | 97% |
| CCL19 (MIP-3beta) | Lyme Disease | Phase II | 85% | 78% |
| IL-6 / sIL-6R ratio | ME/CFS | Phase I | 72% | 81% |
| Tryptophan metabolomics panel | ME/CFS | Phase II | 78% | 83% |
| Substance P (CSF) | Fibromyalgia | Validated | 88% | 72% |
| Micro-RNA panel (miR-let-7d) | Fibromyalgia | Preclinical | 68% | 75% |
| Norepinephrine:DHPG ratio | POTS | Phase II | 82% | 79% |
| Anti-adrenergic receptor Ab | POTS | Phase I | 65% | 91% |
| Spike protein persistence (S1) | Long COVID | Phase II | 75% | 88% |
| Complement C4d fragments | Long COVID | Phase I | 70% | 82% |
| Cortical microstructure (dMRI) | ME/CFS | Preclinical | 74% | 80% |
| Alpha-gal sIgE titer | Alpha-gal Syndrome | Validated | 95% | 92% |
| Mitochondrial complex I activity | ME/CFS | Phase I | 69% | 77% |
| Proteomics: 12-protein classifier | Long COVID | Phase III | 84% | 86% |
Sensitivity and specificity values represent reported performance from published studies and clinical trials. Validated biomarkers have undergone multi-center confirmation.
Cumulative number of validated and candidate biomarkers identified across all invisible illness conditions. The post-2020 acceleration reflects Long COVID research investment catalyzing discoveries across related conditions.
Pharmacogenomics enables treatment personalization based on individual genetic profiles. Key applications in invisible illness management include:
CYP2D6 poor metabolizers may not activate codeine or tramadol. Ultra-rapid metabolizers risk toxicity. Genotyping guides analgesic selection for fibromyalgia and ME/CFS pain.
COMT Val158Met status predicts response to duloxetine and milnacipran in fibromyalgia. Met/Met carriers show enhanced response to norepinephrine-targeting therapies.
HLA typing informs risk of autoimmune progression in treatment-resistant Lyme (DR4+) and guides immunomodulatory therapy selection in Long COVID.
ACE2 receptor variant profiling helps predict Long COVID risk and may guide early antiviral intervention timing and dosing.
Provides ancestry + health risk reports. Covers COMT, MTHFR, CYP2D6, and select HLA alleles. Useful as a screening tool but not diagnostic-grade for rare variants.
Comprehensive protein-coding gene analysis. Identifies rare variants in connective tissue genes (EDS), immune regulatory genes, and metabolic pathway genes. Insurance may cover with clinical indication.
High-resolution HLA class I and II typing. Identifies DR4, DR2, DRB1*15:01, DQB1*06:02 and other alleles associated with treatment-resistant Lyme, ME/CFS, and Long COVID susceptibility.
Answer the following questions to estimate your familial risk profile. This is a screening tool and does not replace clinical genetic counseling.
1. Do any first-degree relatives (parents, siblings, children) have a diagnosed autoimmune condition?
2. Has anyone in your family been diagnosed with ME/CFS, fibromyalgia, or POTS?
3. Do you or close family members have joint hypermobility or Ehlers-Danlos syndrome?
4. Is there a family history of allergic or atopic conditions (asthma, eczema, severe allergies)?
5. Have any family members experienced prolonged post-infectious symptoms (e.g., post-Lyme, Long COVID)?